12:00 AM
Jun 15, 2015
 |  BC Week In Review  |  Clinical News  |  Regulatory

Akynzeo netupitant/palonosetron regulatory update

The European Commission approved Akynzeo netupitant/palonosetron to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or moderately emetogenic cancer chemotherapy....

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >